CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (40,720)	$ (44,238)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,009	1,054
Stock-based compensation expense	4,362	4,741
Write-off of equipment	215	224
Other	(11)	25
Changes in assets and liabilities:
Accounts receivable	(2,767)	(1,086)
Unbilled receivables	(1,407)	(488)
Inventory	562	(2,209)
Prepaid expenses and other current assets	(222)	1,496
Due from related parties	0	48
Prepaid inventory	693	(412)
Other long term assets	325	(220)
Accounts payable	382	533
Deferred grant funding	(593)	(123)
Deferred revenue	93	(483)
Due to related parties	0	61
Accrued expenses and other current liabilities	(683)	(742)
Operating lease liabilities, net	(5)	10
Net cash used in operating activities	(38,767)	(41,809)
Cash flows from investing activities:
Purchases of property and equipment	(383)	(804)
Net cash used in investing activities	(383)	(804)
Cash flows from financing activities:
Proceeds from exercise of stock options	171	174
Proceeds from shares issued under ATM Sales Agreement, net of selling costs	848
Net cash provided by financing activities	1,019	174
Net decrease in cash and cash equivalents and restricted cash	(38,131)	(42,439)
Cash, cash equivalents and restricted cash, beginning of year	75,804	118,243
Cash, cash equivalents and restricted cash, end of year	37,673	75,804
Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets
Cash and cash equivalents	37,645	75,183
Restricted cash	28	621
Total cash, cash equivalents and restricted cash	37,673	75,804
Supplemental disclosure of cash flow information:
Cash received from exchange of research and development tax credits	0	519
Supplemental disclosure of noncash information:
Noncash acquisition of fixed assets	$ 765	$ 3